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Antisense oligonucleotides are potentially powerful
tools for selective control of cellular and viral gene ex-
pression. Crucial to successful application of this ap-
proach is the specificity of the oligonucleotide for the
chosen RNA target. Here we apply DNA array technol-
ogy to examine the specificity of antisense oligonucleo-
tide treatments. The molecules used in these studies
consisted of phosphorothioate oligomers linked to the
Antennapedia (Ant) delivery peptide. The antisense oli-
gonucleotide component was complementary to a site
flanking the AUG of the MDR1 message, which codes for
P-glycoprotein, a membrane ATPase associated with
multidrug resistance in tumor cells. Using a DNA array
of 2059 genes, we analyzed cellular responses to mole-
cules comprised of Ant peptide-oligonucleotide conju-
gates, as well as to the Ant peptide alone. Besides the
expected reduction in MDR1 message level, 37 other
genes (2% of those tested) showed changes of compa-
rable magnitude. The validity of the array results was
confirmed for selected genes using Northern blots to
assess messenger RNA levels. These results suggest that
studies using antisense oligonucleotide technology to
modulate gene expression need to be interpreted with
caution.
Antisense oligonucleotides have proven to be powerful tools
for selective regulation of gene expression in experimental set-
tings and are currently being evaluated for their therapeutic
potential in the clinic (1, 2). Crucial to both experimental and
therapeutic applications of antisense is the issue of specificity.
Although some studies have shown that antisense oligonucleo-
tides can discriminate differences in target RNAs as small as a
single base change (3), other studies have suggested that oli-
gonucleotides can have biological effects that are not attribut-
able to specific degradation or blockade of their target RNAs.
These effects can be due to sequence-specific aptameric effects
of oligonucleotides (4), to non-sequence-specific binding of oli-
gonucleotides to proteins (5), or to RNA cleavage because of
partial sequence matches (6). In addition, it is possible that the
reagents used to deliver oligonucleotides to cells, including
cationic liposomes (7, 8), polymers (9), or the type of delivery
peptide used in this study (10) could also have effects on cellu-
lar processes that lead to changes in mRNA levels. To guard
against these potentially artifactual effects, investigators in
the field have largely adopted a set of standards and controls
that must be met before claiming a specific antisense action
(11). Although these criteria have been invaluable to this point,
recent technological advances now permit even more stringent
evaluation of the effects of antisense oligonucleotides.
In this report we have used DNA arrays to assess the selec-
tivity of a set of antisense and control reagents that we have
reported on previously (12). Thus we have synthesized and
evaluated peptide-oligonucleotide conjugates comprised of an
oligonucleotide sequence targeted to the AUG region of the
MDR1 gene or its mismatch control. These were both conju-
gated to a 19-amino acid sequence (Ant), adapted from the
antennapedia transcription factor, that is known to be useful
for intracellular delivery of peptides and oligonucleotides (10).
Cells were treated with the peptide-oligonucleotide conjugates,
with the Ant peptide itself, or were maintained as untreated
controls. Thereafter, message levels from 2059 genes were as-
sessed using commercial, oligonucleotide-based DNA array
technology (13, 14). In addition to the expected decrease in
MDR1 message level, 37 additional genes displayed changes
that were regarded as significant in comparing the three ex-
perimental conditions with the control situation.
MATERIALS AND METHODS
Cells—The multidrug-resistant cell line MES-SA/Dx5 was obtained
from the ATCC. This line, originally obtained from uterine sarcoma
fibroblasts, expresses high levels of MDR-1 mRNA and P-glycoprotein
(15). The cells were grown in McCoy’s medium containing 10% fetal calf
serum and 60 ng/ml colchicine in an atmosphere of 95% air, 5% CO2.
Peptide-Oligonucleotide Conjugate Synthesis—Peptide-oligonucleo-
tide conjugates were prepared via disulfide bond formation. Specific-
ally, phosphorothioate 20-mer anti-MDR1 5-d(CCA-TCC-CGA-CCT-
CGC-GCT-CC)-3 and mismatch 5-d(CCA-TAC-CAA-CAT-CAC-GCT-
CC)-3 oligonucleotides were conjugated with highly basic Ant peptide
(NH2RQIKIWFQNRRMKWKKGGCCOOH), and the conjugates were pu-
rified by high pressure liquid chromatography as previously described
(12). The conjugates also included a TAMRA (carboxylic acid of tetra-
methylrhodamine) fluorophore at the 3-end. The 20-mer anti-MDR1 oli-
gonucleotide was also used in unconjugated form in some studies below.
Treatment of Cells with Peptide-Oligonucleotide Conjugates—The
experimental protocols were similar to those previously described (12).
Briefly, MES-SA/Dx5 cells were grown in 162-mm flasks to 95% con-
fluency and then seeded into 100-mm dishes at 2  106/dish in 10% fetal
bovine serum (FBS)/McCoy’s medium1 and incubated for 24 h. The cells
were washed twice with PBS (phosphate-buffered saline). The peptide-
oligonucleotide conjugates or Ant peptide itself were diluted in 10%
FBS/McCoy’s medium to 0.5 M and were added into the cells and
incubated at 37 °C for 16 h; after a medium change, the cells were
assayed 48 h later. This protocol was used for the DNA array, Northern
blotting, and flow cytometry experiments described below.
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Scrape Loading of Antisense Oligonucleotides—We also used a
scrape-loading procedure (16) to transiently disrupt cell membranes
and allow direct loading of unconjugated oligonucleotides into MES-SA/
Dx5 cells. Briefly, the cells were seeded 24 h before treatment in
100-mm dishes at 1.5  106 cells/dish in 3 ml of medium. For scrape
loading the medium was replaced with 3 ml of growth medium contain-
ing 0.5 M 20-mer anti-MDR1 oligonucleotide. Cells were then removed
from the plate with a cell scraper (Costar, Corning, NY), replated in
fresh medium, and assayed 48 h later.
Analysis of P-glycoprotein Levels—Cell surface expression of P-gly-
coprotein was determined using a flow cytometry assay as previously
described (12). After treatment with the conjugates, cells were washed
twice in PBS, trypsinized, and resuspended in 10% FBS/McCoy’s me-
dium. The cells were washed in PBS, and 50 l of 20 g/ml MRK16
anti-P-glycoprotein antibody (Kamiya, Thousand Oaks, CA) was added.
After incubation for 45 min on ice, cells were washed three times in 10%
FBS/PBS and then incubated 30 min with an FITC conjugated goat
anti-mouse IgG (Sigma). After the incubation, the cells were washed
twice in 10% FBS/PBS. The level of FITC fluorescence in viable cells
(viability determined by light scatter) was quantitated using the Sum-
mit V3.0 software application (Cytomation Inc.) on a Becton Dickinson
flow cytometer.
RNA Isolation—Cytoplasmic RNA was isolated from the cells using a
kit according to a protocol suggested by the manufacturer (Qiagen Inc.,
Valencia, CA). The RNA concentration was measured by taking the
A260 nm.
DNA Array Analysis—Array studies were conducted in a manner
similar to those described elsewhere (17, 18). Isolated cytoplasmic RNA
(0. 7 g) was used to synthesize cDNA. A custom cDNA kit from
Invitrogen was used with a T7-(dT)24 primer for this reaction. Biotiny-
lated cRNA was then generated from the cDNA reaction using the
BioArray high yield RNA transcript kit (Affymetrix). The cRNA was
then fragmented (5 fragmentation buffer: 200 mM Tris acetate, pH
8.1, 500 mM KOAc, 150 mM MgOAc) at 94 °C for 35 min before chip
hybridization. Following the manufacturer’s protocol, fragmented
cRNA (15 g) was added to the hybridization mixture. DNA arrays
HC-G110 or HG-U95Av2 (Affymetrix) were hybridized for 16 h in a
GeneChip Fluidics Station 400 and scanned with a Hewlett Packard
GeneArray Scanner. Sample quality was assessed by examination of 3
to 5 intensity ratios of certain genes. Samples were normalized to the
average hybridization intensity on each chip. All array studies were
performed as three to six independent experiments. Affymetrix Gene-
Chip Microarray Suite 4.0 software was used for the experimental
protocol and for basic analysis. The Gene Spring 4.0.2 (Silicon Genetics)
software package was used for additional data analysis.
Measurement of mRNA Levels—Northern blotting was done accord-
ing to a standard protocol (19). Briefly, cytoplasmic RNA was isolated
from the cultured cells according to a protocol suggested by the manu-
facturer (Qiagen Inc.). Five micrograms of RNA sample was resolved on
a 0.8% agarose gel containing 1.2% formaldehyde and transferred into
a nylon membrane, followed by UV cross-linking (Stratagene, La Jolla,
CA). The blot was hybridized with 32P-labeled human cDNA probes.
The templates for the probes were gel-purified (gel purification kit,
Qiagen Inc.) reverse transcription-PCR products of: human MDR1 with
the forward primer 5-ACC GCA ATG GAG GAG CAA AG-3 and the
reverse primer 5-TTA AGC TCC CCA ACA TCG TG-3; human PKC
with the forward primer 5-CCT TCC AAC AAC CTT GAC C-3 and the
reverse primer 5-TCG TGA CTC CAT CCA TCA TG-3; leukocyte
tyrosine kinase with the forward primer 5-CCA TTC TCT GCT CTA
GCC-3 and the reverse primer 5-GGG CAC AGG CAT TCA GCC-3;
-actin with the forward primer 5-CTT CCT TCC TGG GCA TGG A-3
and the reverse primer 5-AGG AGG AGC AAT GAT CTT GA-3. The
probes were synthesized by a random priming method using a commer-
cial kit (Ambion, Inc., Austin, TX). The hybridized blot was washed
twice with 2 SSC buffer at room temperature, followed by two washes
of 2 SSC  1% SDS at 60 °C and two washes of 0.1 SSC at room
temperature. The blot was then exposed to Kodak film for 6–24 h prior
to development.
RESULTS AND DISCUSSION
The effects of the Ant peptide-oligonucleotide conjugates in
inhibiting expression of P-glycoprotein are illustrated in Fig. 1.
Cell surface levels of P-glycoprotein were quantitated by flow
cytometry, using an antibody that is directed to a P-glycopro-
tein epitope displayed on the external surface of cells, followed
by a fluorescent second antibody (12). As expected based on
previous studies (12), we observed substantial inhibition of
P-glycoprotein expression in cells treated with the antisense
Ant 20 conjugate (Fig. 1D) and little effect in cells treated with
the mismatch control conjugate (Fig. 1C, Ant 20 mismatch).
Treatment with unconjugated antisense oligonucleotide or
with the Ant peptide itself had no effect on P-glycoprotein
levels (Ref. 12 and data not shown). The degree of inhibition of
P-glycoprotein levels in the flow cytometry studies was 85%
for Ant 20 and 2% for Ant 20 mismatch versus untreated
control.
To provide a broader perspective on the specificity of our
peptide-oligonucleotide conjugates, we used Affymetrix DNA
array technology to interrogate a set of 2059 cancer-related
FIG. 2. DNA array analysis of MDR1 gene expression. The rel-
ative hybridization intensity is shown with the untreated control nor-
malized to 1.0. Black bar, untreated control; gray bar, antisense Ant 20
treatment; white bar, Ant 20 mismatch treatment. The data represent
the means  S.E. of three to six independent experiments.
FIG. 1. Antisense inhibition of P-glycoprotein expression
measured by flow cytometry. Approximately 10,000 MES-SA/Dx5
cells were counted in each sample. The abscissa represents the amount
of bound fluorescent antibody. The ordinate is the number of cells at
each level of fluorescence. A, unstained, untreated control (no primary
antibody); B–D, samples immunostained with MRK16 anti-P-glycopro-
tein antibody; B, untreated control; C, Ant 20 mismatch treatment; D,
antisense Ant 20 treatment. The bimodal shape of the peaks in B–D
suggests some heterogeneity in P-glycoprotein expression in the origi-
nal drug-resistant cell population.
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genes. As seen in Fig. 2, the array data on the MDR1 gene
agrees with the observations of Fig. 1 and shows a substantial
reduction (about 3-fold) in MDR1 message expression in the
cells treated with the Ant peptide-antisense conjugate but not
in cells treated with the control mismatch conjugate. We next
sought other genes whose message levels changed significantly
from untreated control levels in response to one of the three
experimental treatments. The following criteria were used to
identify such genes: (a) there must be at least a 2-fold change in
message level as compared with untreated control; (b) the
hybridization intensity must be above 100 arbitrary units so as
to exclude weak signals; (c) the standard deviation between
experiments must be less than 100% of the relative intensity so
as to exclude genes that did not change in a consistent manner
in the several independent experiments. These are similar to
criteria used in several other studies (13, 14). Based on these
criteria, 38 genes including MDR1 were identified (Table I),
which is 2% of the genes sampled. Both increases and de-
creases in gene expression were observed. As shown in Table I,
and in more detail in Table II, the selected genes can be divided
into three different clusters. These are: (a) genes specifically
affected by a particular peptide-oligonucleotide conjugate
(genes affected by Ant 20 or by Ant 20 mismatch); (b) genes
affected by treatment with both antisense and mismatch con-
trol conjugates (genes affected by both Ant 20 and Ant 20
mismatch); (c) genes affected by the presence of the Ant peptide
(genes affected by Ant 20, Ant 20 mismatch, and Ant). Thus
cells can respond through changes in gene expression to par-
ticular oligonucleotide sequences, to the intracellular presence
of peptide-oligonucleotide conjugates in a sequence-indepen-
TABLE II
DNA array analysis of genes affected by peptide-oligonucleotide conjugates
The identity of the genes affected by peptide oligonucleotide conjugates and the approximate magnitude of the increase or decrease are indicated.
p values (Student’s t test) for treated versus untreated controls are shown. Genes whose message levels were affected by both anti-MDR1
peptide-oligonucleotide conjugate and by “free” anti-MDR1 oligonucleotide delivered by scrape loading are indicated with number symbols adjacent
to the name of the gene. The data for the Ant 20 (antisense) conjugate represents six independent experiments. The data for the Ant 20 mismatch
and the unconjugated Ant peptide represent three independent experiments.











Human MEK5 (3) 0.051 * *
Human tissue inhibitor of metalloproteinases-3 (3) 0.043 * *
Human PKC  (2) 0.041 * *
Human stem cell leukemia (2) 0.014 *
Human heat shock factor 1 (TCF5) (2) 0.048 *
Human oncostatin-M specific receptor  (2) 0.002 *
DNA polymerase  catalytic subunit # (2) 0.018 *
Human T-cell receptor active -chain # (2) 0.005 * *
Retinoic acid receptor, 2 (2) 0.089 * *
Human MDR1 # (3) 0.004 *
Human leukocyte tyrosine kinase (3) 0.035 *
Human DNA topoisomerase III (3) 0.040 * *
Homo sapiens TGF- type I receptor # (3) 0.025 *
Human mdm2-E (mdm2) # (2) 0.032 *
Integrin 3 (alternatively spliced) # (2) 0.019 *
Human interleukin-8 receptor type A # (2) 0.008 *
Human c-erbA # (2) 0.109 *
Human prolactin # (2) 0.023 *
Mitogen-induced nuclear orphan receptor # (2) 0.047 *
Homo sapiens vasopressin V3 receptor (2) 0.015 *
CD44 gene (cell surface glycoprotein CD44) (3) 0.042 *
Human transforming growth factor-1 (2) 0.005 *
Homo sapiens DNA ligase IV (2) 0.045 *
Homo sapiens transmembrane tyrosine kinase (3) 0.016 *
Human G protein-coupled receptor OGR1 (2) 0.080 *
Ubiquitin-conjugating enzyme Ubch5 (2) 0.008 *
Human TR3 orphan receptor (2) 0.069 *
Human cytochrome P450 (CYP2A13) (2) 0.056 *
Homo sapiens interleukin 1 (IL-1) (2) 0.060 *
Human Src-like adapter protein (2) 0.030 *
Human SH3 domain-containing protein (3) 0.095 *
Human GTPase-activating protein (rap1GAP) (2) 0.064 *
Granulocyte colony-stimulating factor receptor (3) 0.020 *
Oncogene Aml1-Evi-1, fusion activated (2) 0.009 *
Bcl-2 mRNA (3) 0.011 * * *
Human C-C chemokine receptor type (3) 0.015 * * *
Human protein kinase (JNK1) (2) 0.001 * * *
Homo sapiens cadherin (2) 0.036 * * *
TABLE I
Compilation of genes affected by peptide-oligonucleotide conjugates
The number of genes significantly affected by a particular treatment is shown. The criteria for attributing significance are discussed in the text.











Genes affected by Ant 20 24 13 11 14 4 10
Genes affected by Ant 20 mismatch 20 12 8 10 3 7
Genes affected by Ant 8 6 2 4 2 2
Genes affected by both Ant 20 and Ant 20 mismatch 10 9 1
Genes affected by Ant 20 and Ant 20 mismatch and Ant 4 4 0
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dent fashion, or to the presence of the polycationic delivery
peptide. The affected genes did not belong to any obvious func-
tional group or pathway.
These experiments were repeated in triplicate using a 10-
fold lower concentration of anti-MDR1 peptide-oligonucleotide
conjugate. As expected based on previous studies (12), there
was a much weaker impact on P-glycoprotein levels as meas-
ured by flow cytometry and on MDR1 message levels measured
by DNA array analysis (data not shown). Likewise there were
fewer substantial changes in message levels of non-target
genes with only 6 of the 24 genes previously identified as
responsive to peptide-oligonucleotide conjugates showing
changes that fit our criteria. Thus, there seem to be clear-cut
dose-response relationships in this system for both the target
gene and non-target genes.
DNA array technology gives the opportunity for simultane-
ous analysis of thousands of genes. However, because of the
global character of this type of analysis and the possibility of
errors, array data need to be confirmed by other independent
approaches. To provide verification of the changes in message
levels seen in the array analysis we performed Northern blots.
Four different genes were chosen including MDR1, the target
gene, -actin as a “housekeeping gene” control, and two of the
genes that responded significantly to treatment with peptide-
oligonucleotide conjugates. According to the array data, leuko-
cyte tyrosine kinase expression was predicted to be decreased
by exposure to Ant 20 but not other treatments, whereas pro-
tein kinase C  was predicted to be increased by exposure to
either Ant 20 or Ant 20 mismatch. As seen in Fig. 3, A–D, the
Northern blot data confirmed the array analysis. Thus MDR1
and leukocyte tyrosine kinase message levels were decreased
by exposure to Ant 20, whereas PKC was increased by treat-
ment with either conjugate. Actin message levels remained
approximately constant. The magnitude of the decrease in
MDR1 mRNA detected by Northern blotting, as well as the
change in the level of P-glycoprotein (Fig. 1), were both about
4–5-fold, although the DNA array results (Fig. 2) indicated an
average MDR1 message reduction of 3-fold. This seems a rea-
sonable level of agreement given the very divergent assays
used.
The experiments reported above have dealt with peptide-
oligonucleotide conjugates or “free” peptide. However, one
might ask whether the observed effects might be different if
free antisense oligonucleotide was used instead. To address
this issue, a 20-mer anti-MDR1 oligonucleotide was delivered
FIG. 4. Venn diagram of genes affected by peptide-oligonucle-
otide conjugates versus free oligonucleotide. The diagram com-
pares the overlap of genes affected by anti-MDR1 peptide-oligonucle-
otide conjugates with those affected by free oligonucleotide delivered by
scrape loading. The white area indicates the 10 genes affected by both
treatments. The purple area indicates the 14 genes affected by the
conjugates only (also described in Table II). The blue-green area indi-
cates the 30 genes affected by scrape-loaded oligonucleotide only (the
characteristics of these genes were not pursued further). The gray area
represents the residual 2005 genes not affected by either treatment.
FIG. 5. Sequence comparison of antisense oligonucleotides
with down-regulated genes. The three genes whose message levels
were reduced by both anti-MDR1 peptide-oligonucleotide conjugate and
by free anti-MDR1 oligonucleotide are indicated duplexed with the
20-mer anti-MDR1 oligonucleotide. Consensus sequences, mismatches,
and predicted melting temperatures (Tm) are shown. TGF, transform-
ing growth factor.
FIG. 3. Northern blotting analysis. Northern blotting was per-
formed as described in the text. A, MDR1 gene; B, -actin gene; C,
human leukocyte tyrosine kinase gene; D, human PKC gene. Untr,
untreated control MES-SA/Dx5 cells; Ant 20, cells treated with anti-
sense peptide-oligonucleotide conjugate; Ant 20 mismatch, cells treated
with mismatch peptide-oligonucleotide conjugate.
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to cells using a “scrape-loading” process (16). This resulted in
effective reduction in P-glycoprotein levels, similar to that at-
tained with the anti-MDR1 peptide-oligonucleotide conjugate
(evaluated by flow cytometry, data not shown). The same cri-
teria were then used in these experiments, as in the experi-
ments with peptide-oligonucleotide conjugates, to identify ad-
ditional genes that we deemed to display significant changes in
mRNA levels (Fig. 4). Interestingly, of the 24 genes whose
mRNA levels were affected by the anti-MDR1 conjugate (see
Table II), 10 were also affected by free antisense oligonucleo-
tide delivered by scrape loading. The effects on these 10 genes
likely represent actions of the antisense oligonucleotide moiety
itself; conversely, effects on the other 14 genes probably are due
to joint actions of the oligonucleotide and its associated delivery
peptide. Thus, our observations indicate that there can be
distinct effects on non-target genes because of the oligonucleo-
tide alone, the delivery peptide alone, or the peptide-oligonu-
cleotide conjugate.
In an attempt to better understand the basis of the observed
changes in message levels upon treatment, the non-target
genes were analyzed for possible direct interactions with the
oligonucleotides used in this study. The complete sequences of
all the genes that showed substantial changes in expression
were recovered from the NCBI Draft Human Genome data
base. The Vector NTI program was used in the Analyze Oligo
Duplexes mode to compare possible expressed sequences with
the sequence of the MDR1 antisense or mismatched oligonu-
cleotides. Although no precise complementarities were ob-
served, three of the genes whose message levels were reduced
by both anti-MDR1 peptide-oligonucleotide conjugate and by
scrape loading free anti-MDR1 oligonucleotide showed 75–80%
complementarity, with predicted melting temperatures at or
above physiological levels (Fig. 5). Thus these messages could
potentially be targets for true antisense action. However, the
lack of complementarity in many of the affected genes suggests
that most of the observed changes in message levels in non-
target genes were because of indirect effects of the oligonucleo-
tides on cellular regulatory processes rather than to sequence-
specific complexation with the mRNAs. Such indirect effects
might include interactions with certain proteins in particular
signaling and/or transcriptional regulation pathways.
Current results indicate that treatment of cells with peptide-
antisense oligonucleotide conjugates can cause both specific
reduction in the target mRNA as well as increases or decreases
in a number of irrelevant mRNAs. These results buttress the
concept that antisense experiments must be interpreted cau-
tiously. However, our results do not negate the value of anti-
sense as an experimental tool or a possible therapeutic ap-
proach. For several reasons, the results presented here may
reflect an unusually high degree of nonspecific effects. First,
because the MDR1 gene is a challenging target for antisense
inhibition (20), we used rather high (M) levels of oligonucleo-
tide conjugates. In some other cases effects of comparable mag-
nitude on the target gene have been obtained with much lower
(nM) levels of antisense oligonucleotide (21); this would tend to
reduce nonspecific interactions. Second, current studies in-
volved phosphorothioate oligonucleotides; these are known to
have substantially more nonspecific binding to proteins (22)
than newer chemical forms of oligonucleotides (23) and thus a
greater propensity for nonspecific effects (24). Finally, one
should consider that, even in the present case, only 2% of the
tested genes showed changes in message levels that were
deemed to be significant according to our criteria, whereas
most genes were not significantly affected. Thus it seems that
antisense oligonucleotides can have substantial, though not
perfect, selectivity as reagents for gene regulation.
It is interesting to note that the observations presented here
provide quite a different picture than that resulting from an-
other recent study of antisense effects using DNA array anal-
ysis (25). In that study antisense oligonucleotides were tar-
geted to the message for one of the subunits of protein kinase A,
a key growth regulatory protein. In addition to changes in PKA
RI subunit expression, many other changes in gene expres-
sion were observed as well as changes in cell growth; however,
these were interpreted as being “downstream” of the effects on
PKA. In our studies the levels of peptide-oligonucleotide con-
jugates used have no effect on cell growth (26), and thus the
effects we see on non-target genes likely represent nonspecific
actions of the antisense molecules rather than action on a
coordinated growth regulatory program.
In summary, our results indicate that peptide-oligonucleo-
tide conjugates, as well as unconjugated oligonucleotides, can
have both specific antisense effects on target genes as well as
significant nonspecific effects on irrelevant genes. These re-
sults do not contravene the utility of antisense as a research
tool or treatment modality. However, proper interpretation of
antisense studies should include the best tools available for
evaluating selectivity; clearly DNA arrays will be important in
that regard.
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